Rakovina Therapeutics Inc. RKV.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.74M | 2.29M | 2.82M | 2.59M | 2.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.70M | 5.60M | 6.00M | 5.70M | 5.20M |
| Operating Income | -4.70M | -5.60M | -6.00M | -5.70M | -5.20M |
| Income Before Tax | -5.12M | -5.98M | -6.28M | -5.98M | -5.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.12 | -5.98 | -6.28 | -5.98 | -5.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.12M | -5.98M | -6.28M | -5.98M | -5.43M |
| EBIT | -4.70M | -5.60M | -6.00M | -5.70M | -5.20M |
| EBITDA | -4.31M | -5.21M | -5.61M | -5.32M | -4.82M |
| EPS Basic | -0.23 | -0.31 | -0.37 | -0.41 | -0.43 |
| Normalized Basic EPS | -0.14 | -0.19 | -0.23 | -0.25 | -0.27 |
| EPS Diluted | -0.23 | -0.32 | -0.37 | -0.41 | -0.43 |
| Normalized Diluted EPS | -0.14 | -0.19 | -0.23 | -0.25 | -0.27 |
| Average Basic Shares Outstanding | 88.87M | 80.37M | 72.32M | 61.16M | 48.98M |
| Average Diluted Shares Outstanding | 88.87M | 80.37M | 72.32M | 61.16M | 48.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |